Chinese English Japanese Germany Korea


라미부딘 구조식 이미지
카스 번호:
포뮬러 무게:
MOL 파일:

라미부딘 속성

177 °C
D21 -135° (c = 0.38 in methanol)
-142 ° (C=1, MeOH)
저장 조건
water: soluble10mg/mL, clear
물리적 상태
white to beige
CAS 데이터베이스
134678-17-4(CAS DataBase Reference)
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험 카페고리 넘버 63-36/37/38
안전지침서 26-36
유엔번호(UN No.) UN1230 - class 3 - PG 2 - Methanol, solution
WGK 독일 3
RTECS 번호 UW7361333
HS 번호 29349990
유해 물질 데이터 134678-17-4(Hazardous Substances Data)
신호 어: Danger
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H225 고인화성 액체 및 증기 인화성 액체 구분 2 위험 P210,P233, P240, P241, P242, P243,P280, P303+ P361+P353, P370+P378,P403+P235, P501
H361 태아 또는 생식능력에 손상을 일으킬 것으로 의심됨 생식독성 물질 구분 2 경고 P201, P202, P281, P308+P313, P405,P501
H370 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킴(노출되어도 특정 표적장기 독성을 일으키지 않는다는 결정적인 노출경로가 있다면 노출경로를 기재) 특정 표적장기 독성 - 1회 노출 구분 1 위험 P260, P264, P270, P307+P311, P321,P405, P501
P201 사용 전 취급 설명서를 확보하시오.
P210 열·스파크·화염·고열로부터 멀리하시오 - 금연 하시오.
P260 분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P281 요구되는 개인 보호구를 착용하시오
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P403+P233 용기는 환기가 잘 되는 곳에 단단히 밀폐하여 저장하시오.

라미부딘 MSDS


라미부딘 C화학적 특성, 용도, 생산


라미부딘 (Lamivudine)은 역전사 효소 억제제이며, 황 원자가 5 탄당 고리의 3 '탄소를 대체하는 잘시 타빈 유사체이다.


그것은 인간 면역 결핍 바이러스를 예방하고 치료할 수있는 항 바이러스 활성 성분입니다. 라미부딘은 우리 몸에 B 형 간염 바이러스가 번식하는 것을 막을 때도 효과적입니다. 라미부딘은 경구 투여 후에 매우 빠르게 흡수됩니다.


Lamivudine is a new generation orally active nucleoside analog launched in the U.S.A. for use in combination with zidovudine (AZT) as a first-line therapy for patients with HIV infection. Lamivudine is rapidly converted to phosphorylated metabolites in the body which act as inhibitors and chain terminators of HIV reverse transcriptase (RT), the enzyme required for the replication of the HIV genome. Lamivudine has similar inhibitory potency to RT as AZT but is 10 times less toxic and is active against AZT-resistant strains of HIV. Combination therapy of lamivudine and AZT produced a large decrease in blood-borne virus with an increase in CD4 cells, an effect that can be sustained for 2 years. Since hepatitis B virus (HBV) also encodes a polymerase with a RT function necessary for the conversion of a RNA replicative intermediate to DNA, clinical efficacy has been reported for lamivudine in treating patients with HBV infection. It was reported that the enantiomer of lamivudine is equipotent against HIV but with considerably higher cytotoxicity.

화학적 성질

White Crystalline Powder


BioChem Pharma (Canada)


A reverse transcriptase inhibitor. Antiviral.


ChEBI: A monothioacetal that consists of cytosine having a (2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl moiety attached at position 1. An inhibitor of HIV-1 reverse transcriptase.


Lamivudine is a synthetic cytidine analogue used in the treatment of HIV and HBV. Its activation requires phosphorylation by cellular enzymes. Lamivudine triphosphate competitively inhibits HBV DNA polymerase and HIV reverse transcriptase and causes chain termination. It inhibits the activity of mammalian DNA polymerases with a much lower potency.
HIV-1 frequently acquires mutations in reverse transcriptase that result in resistance to lamivudine within 12 weeks of treatment. Mutations in the DNA polymerase of HBV are associated with decreased lamivudine efficacy and have been documented in patients treated with this agent for 6 months or more.


Epivir (GlaxoSmithKline).


A single codon change at position 184 in the HIV reverse transcriptase gene confers high-level resistance. The K65R mutation is also associated with resistance. In-vitro data indicate that lamivudine resistance may restore HIV sensitivity to zidovudine- and tenofovir-resistant virus.

일반 설명

Lamivudine is (-)-2',3'-dideoxy-3'-thiacytidine, (-)-β-L-(2R,5S)-1,3-oxathiolanylcytosine, 3TC, or (-)-(S)-ddC.Lamivudine is a synthetic nucleoside analog that differsfrom 2β,3β-dideoxycytidine (ddC) by the substitution of asulfur atom in place of a methylene group at the 3'-positionof the ribose ring. In early clinical trials, lamivudine exhibitedhighly promising antiretroviral activity against HIVand low toxicity in the dosages studied.Preliminarypharmacokinetic studies indicated that it exhibited goodoral bioavailability (F=~80%) and a plasma half-life of 2to 4 hours.

Pharmaceutical Applications

An analog of cytidine available for oral administration.

Pharmaceutical Applications

An antiretroviral agent that also exhibits activity against hepatitis B virus and duck hepatitis B virus. Its properties are described in Ch. 36 . Use is limited by the development of resistance within 1 year in up to 25% of treated patients. It is likely to be used with other drugs in the future.


Oral absorption: 80–85%
Cmax, 300 mg once daily: 2.0 mg/L
Plasma half-life: 5–7 h
Volume of distribution: 1.3 L/kg
Plasma protein binding: <36%
It is rapidly absorbed and there is no significant difference in bioavailability when taken with food.
It penetrates moderately well into the CNS. The semen:plasma ratio is about 9.1 (2.3–16.1). It is secreted into breast milk.
Metabolism and excretion
Less than 10% of the administered dose undergoes hepatic metabolism. Over 70% of the dose is subject to renal clearance via active tubular secretion. Dosage adjustments are not routinely recommended in the presence of renal or hepatic impairment.

Clinical Use

Therapy of chronic hepatitis B

Clinical Use

Lamivudine is indicated for the treatment of HIV when used in combination with other antiretroviral agents.A lower dose than that used to treat HIV is approved for the treatment of HBV. Although lamivudine initially improves histological and biochemical measures of hepatic function and reduces HBV DNA to below the limits of detection, withdrawal of the drug usually results in disease recurrence. Resistance appears in up to onethird of patients after 1 year of treatment.


Lamivudine is relatively safe and non-toxic. Animal studies of very high doses did not result in any organ toxicity. In patients co-infected with HIV and HBV, cessation of lamivudine therapy may result in clinical and/or laboratory evidence of recurrent hepatic disease that may be more severe in patients with hepatic decompensation. Tests of liver function and inflammation and markers of HBV replication should be periodically monitored.
Lamivudine competes with emtricitabine for the enzymes involved in intracellular phosphorylation and co-administration is contraindicated.


The most common adverse effects of lamivudine seen at doses used to treat HBV are mild; they include headache, malaise, fatigue, fever, insomnia, diarrhea, and upper respiratory infections. Elevated alanine aminotransferase (ALT), serum lipase, and creatine kinase may also occur. The safety and efficacy of lamivudine in patients with decompensated liver disease have not been established. Dosage adjustment is required in individuals with renal impairment. Coadministration of trimethoprim–sulfamethoxazole decreases the renal clearance of lamivudine.

라미부딘 준비 용품 및 원자재


준비 용품

라미부딘 공급 업체

글로벌( 380)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 China 886 50
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3194 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 21668 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1817 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32447 55
020-81716319 CHINA 2543 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682; +8618874586545
02783214688 CHINA 535 55
career henan chemical co
+86-371-86658258 CHINA 30002 58
Shaanxi Yikanglong Biotechnology Co., Ltd.
17791478691 CHINA 297 58

라미부딘 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved